 |
|
COX-2 Inhibitors, Other NSAIDs, and Cardiovascular RiskThe Seduction of Common Sense
David J. Graham, MD, MPH
JAMA. 2006;296:1653-1656. Published online September 12, 2006 (doi:10.1001/jama.296.13.jed60058).
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
. . . (A) long habit of not thinking a thing wrong, gives it a superficial appearance of being right, and raises at first a formidable outcry in defence of custom. But the tumult soon subsides. Time makes more converts than reason.—Thomas Paine, Common Sense, 1776
The concept was appealing in its simplicity. Traditional nonsteroidal anti-inflammatory drugs (NSAIDs) inhibited both isoforms of the enzyme cyclooxygenase responsible for the first step in the conversion of arachidonic acid into a variety of prostaglandins, thromboxanes, and leukotrienes throughout the body.1 The anti-inflammatory and pain-relieving effects of NSAIDs resulted from inhibition of prostaglandin synthesis mediated by cyclooxygenase 2 (COX-2) at the site of tissue injury, while gastrointestinal tract complications were due to inhibition of prostaglandin synthesis mediated by cyclooxygenase 1 (COX-1) in the gastrointestinal mucosa. The allure of COX-2 inhibitors was the prospect of treating pain without gastrointestinal toxicity.1 Celecoxib . . . [Full Text of this Article]
Editor's Note: Dr Graham is an employee of the US Food and Drug Administration. This editorial was written by Dr Graham as an officially approved outside activity in his private capacity and not as a Food and Drug Administration employee. His contact information is publicly available at http://directory.psc.gov/employee.htm and is as follows: David J. Graham, MD, MPH, Office of Surveillance and Epidemiology, Food and Drug Administration, 10903 New Hampshire Ave, WO22, Room 4314, Silver Spring, MD 20993 (david.graham1@fda.hhs.gov).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2
Patricia McGettigan and David Henry
JAMA. 2006;296(13):1633-1644.
ABSTRACT
| FULL TEXT
Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials
Jingjing Zhang, Eric L. Ding, and Yiqing Song
JAMA. 2006;296(13):1619-1632.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The Role of Conflict of Interest in Reporting of Scientific Information
Irwin
Chest 2009;136:253-259.
ABSTRACT
| FULL TEXT
Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Point
Arber
Cancer Epidemiol. Biomarkers Prev. 2008;17:1852-1857.
ABSTRACT
| FULL TEXT
Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease
Hennekens and Borzak
J CARDIOVASC PHARMACOL THER 2008;13:41-50.
ABSTRACT
How can we regulate medicines better?
Garattini and Bertele'
BMJ 2007;335:803-805.
FULL TEXT
Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials
Scott et al.
Ann Rheum Dis 2007;66:1296-1304.
ABSTRACT
| FULL TEXT
Use of Nonsteroidal Antiinflammatory Drugs: An Update for Clinicians: A Scientific Statement From the American Heart Association
Antman et al.
Circulation 2007;115:1634-1642.
FULL TEXT
Clinical Trial Registration Promotes Patient Protection and Benefit, Advances the Trust of Everyone, and Is Required
Irwin
Chest 2007;131:639-641.
FULL TEXT
Overdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation
Rawson
JAMA 2007;297:646-647.
FULL TEXT
Cyclooxygenase Inhibitors and Cardiovascular Risk
Andersohn et al.
JAMA 2007;297:586-587.
FULL TEXT
COX-2 Inhibitors and NSAIDs: More Data on CV Risk
Journal Watch Cardiology 2006;2006:2-2.
FULL TEXT
|
